Progressive Muscle Relaxation for Fatigue and Breathing in Systemic Sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests whether a progressive muscle relaxation program can improve fatigue, dyspnea, and respiratory function in adults with systemic sclerosis. Participants will undergo baseline assessments, complete a period of structured relaxation exercises, and then have post-intervention assessments to measure changes. The study uses a non-drug, exercise-like approach to symptom management and follows standard safety monitoring. Results will indicate whether this technique could be a supportive option alongside usual care for systemic sclerosis. The investigation is conducted at Gaziantep University and involves a single site.

Why it matters

Who can join: the full rules

Inclusion Criteria:Individuals who meet the study eligibility criteria will be included in the study. Eligible participants will be adults aged 18 years or older, diagnosed with systemic sclerosis, and have adequate physical and cognitive capacity to participate in the study.

Exclusion Criteria:Individuals who do not meet the inclusion criteria, who are unable to participate in the progressive muscle relaxation exercises due to their physical or cognitive condition, or who withdraw from the study voluntarily will be excluded from the study.

\-

Where it's running

• Gaziantep University Vocational School of Health Services
  Gaziantep, Şehitkamil, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Adile Neşe, Associate Professor — University of Gaziantep
• Study coordinator: Adile Neşe, Assoc Prof.
• Email: acaparusagi@hotmail.com
• Phone: 03423172187

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FT839 therapy for autoimmune diseases

  This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.

  Recruiting Phase 1/2 Fate Therapeutics · Fullerton, California · NCT07800871

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Tissue models of systemic sclerosis using patient-derived iPSCs

  Researchers will create iPSC lines from people with systemic sclerosis, their healthy relatives, and test them across several cell types to see how the disease affects tissues in the lab.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07650565

• First-in-human test of PRO-203 in healthy adults and people with systemic sclerosis

  Researchers will test a single subcutaneous dose of PRO-203 in healthy adults and in people with systemic sclerosis to see if it is safe and how the body handles it.

  Recruiting at 12 sites Phase 1/2 Prolium Bioscience, Inc · Melbourne, Victoria and 12 other locations · NCT07641634

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

• MTS109 treatment for refractory autoimmune diseases

  This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07526350

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.